1. Academic Validation
  2. Development of dimeric modulators for anti-apoptotic Bcl-2 proteins

Development of dimeric modulators for anti-apoptotic Bcl-2 proteins

  • Bioorg Med Chem Lett. 2008 Jan 1;18(1):236-40. doi: 10.1016/j.bmcl.2007.10.088.
Liangyou Wang 1 Fansen Kong Candis L Kokoski David W Andrews Chengguo Xing
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, University of Minnesota Minneapolis, MN 55455, USA.
Abstract

Bcl-2 Family proteins can be classified into two subfamilies--anti-apoptotic members and pro-apoptotic members. Mechanistically, these two subfamilies can antagonize each other through heterodimerization while homodimerization has been proposed for each subfamily to carry out their corresponding anti-apoptotic or pro-apoptotic functions. To date, many small-molecule antagonists against anti-apoptotic Bcl-2 proteins have been developed, which are monomeric modulators. In this study, a series of BH3I-1 based dimeric modulators were developed with structure-activity relationship explored. Dimeric modulators compared to the monomeric antagonists have enhanced binding activity against anti-apoptotic Bcl-2 proteins. In addition, the acidic functional group was demonstrated to be critical for the binding interaction of the small-molecule antagonists with anti-apoptotic Bcl-2 proteins. Finally, the representative dimeric modulator revealed enhanced activity in inducing cytochrome c release from mitochondria compared to its monomeric counterpart. Taken together, dimerization of monomeric modulators is one practical approach to enhance the bioactivity of Bcl-2 antagonists.

Figures
Products